Details for Patent: 10,584,124
✉ Email this page to a colleague
Which drugs does patent 10,584,124 protect, and when does it expire?
Patent 10,584,124 protects RETEVMO and is included in one NDA.
This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 10,584,124
| Title: | Crystalline forms |
| Abstract: | Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- -diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-car- bonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicy- clo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula III), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-hydroxy-4-(pyridin-2-ylmethyl)piper- idin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula IV), and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, the application relates to novel crystalline forms of Formula I-IV and pharmaceutically acceptable salts thereof useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. |
| Inventor(s): | Metcalf; Andrew T. (Boulder, CO), Fry; David (Boulder, CO), McFaddin; Elizabeth A. (Boulder, CO), Kolakowski; Gabrielle R. (Boulder, CO), Haas; Julia (Boulder, CO), Tang; Tony P. (Boulder, CO), Jiang; Yutong (Boulder, CO) |
| Assignee: | Array Biopharma Inc. (Boulder, CO) |
| Application Number: | 16/156,880 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
More… ↓ |
Recent additions to Drugs Protected by US Patent 10,584,124
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-2826 | TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-2827 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-2828 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE) | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-3450 | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-3451 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE | 213246 | May 8, 2020 | RX | Yes | ⤷ Subscribe | Y | ⤷ Subscribe | U-3452 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,584,124
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST | ⤷ Subscribe | |||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS | ⤷ Subscribe | |||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY | ⤷ Subscribe | |||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY | ⤷ Subscribe | |||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST | ⤷ Subscribe | |||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,584,124
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 113760 | ⤷ Subscribe | |||
| Australia | 2018348161 | ⤷ Subscribe | |||
| Brazil | 112020005463 | ⤷ Subscribe | |||
| Canada | 3079012 | ⤷ Subscribe | |||
| China | 111278822 | ⤷ Subscribe | |||
| Eurasian Patent Organization | 202090695 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
